[1]周小龙 赵晓莹 赵新湘.射血分数正常的肥厚型心肌病患者心肌T1值和T2值研究[J].心血管病学进展,2021,(9):845-848.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
 ZHOU XiaolongZHAO Xiaoying,ZHAO Xinxiang.Study of T1 and T2 Values in Myocardium of Hypertrophic Cardiomyopathy with Normal Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(9):845-848.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
点击复制

射血分数正常的肥厚型心肌病患者心肌T1值和T2值研究()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年9期
页码:
845-848
栏目:
论著
出版日期:
2021-09-25

文章信息/Info

Title:
Study of T1 and T2 Values in Myocardium of Hypertrophic Cardiomyopathy with Normal Ejection Fraction
文章编号:
202101051
作者:
周小龙 赵晓莹 赵新湘
(昆明医科大学第二附属医院放射科,云南 昆明 650000)
Author(s):
ZHOU XiaolongZHAO XiaoyingZHAO Xinxiang
(Department of Radiology,The Second Affiliated Hospital of Kunming Medical University,Kunming 650000,Yunnan,China)
关键词:
心肌病肥厚型心脏磁共振T1T2
Keywords:
CardiomyopathyHypertrophic typeCardiac magnetic resonanceT1T2
DOI:
10.16806/j.cnki.issn.1004-3934.2021.09.000
摘要:
目的 探讨射血分数正常的肥厚型心肌病(HCM)患者心肌T1和T2值与健康人的差异,进一步认知HCM患者心肌组织特征在功能异常前的改变。方法 20例健康志愿者和34例左室射血分数正常的HCM患者纳入研究。所有受试者使用飞利浦Achieva?3.0 T?TX多源发射磁共振仪进行心脏磁共振检查,扫描序列包括心脏磁共振电影成像、Native T1-mapping和T2-mapping。以舒张末期壁厚(EDWT)为基础,将HCM患者的心肌节段分为正常心肌节段(无HCM家族史EDWT<15 mm,有HCM家族史EDWT<13 mm)、肥厚心肌节段(无HCM家族史,EDWT≥15 mm;有HCM家族史,EDWT≥13 mm),与健康对照组进行比较,并进一步行组间比较。结果 与健康对照组相比,HCM患者左室舒张末期容积、左室收缩末期容积 和左室射血分数均未见统计学差异(P>0.05),但HCM患者肥厚节段与非肥厚节段的T1和T2值均升高;与非肥厚节段相比,肥厚节段T1和T2值均增加,室壁增厚率明显下降(P均<0.05)。结论 心脏磁共振组织特征成像参数T1 和T2值可早于心功能参数发现HCM异常;此外,即便心肌厚度正常,T1和T2值均较正常人增高,这提示组织特征的改变先于HCM的形态和功能重构,因此T1和T2值的测量可为HCM早期心肌的改变提供价值。
Abstract:
Objective To investigate the differences between T1 and T2 values of myocardium in patients with hypertrophic cardiomyopathy(HCM) with normal ejection fraction and healthy people,so as to further understand the changes of myocardial tissue characteristics in patients with HCM before functional abnormalities. Methods Twenty healthy volunteers and 34 HCM patients with normal left ventricular ejection fraction(LVEF) were included in the study.All subjects were underwent CMR by Philips Achieva 3.0 T TX multi-source emission MRI. The scanning sequences included cine,native T1 mapping and T2 mapping. On the basis of end-diastolic wall thickn ess(EDWT),the myocardial segments of HCM patients were divided into normal segments(no family history of HCM,EDWT<15 mm;family history of HCM,EDWT<13 mm) and hypertrophic segments(no family history of HCM,EDWT≥15 mm;family history of HCM,EDWT≥13 mm) ,which were compared with healthy controls and further compared between groups. Results Compared with the healthy control group,there were no statistically significant differences in left ventricular end-diastolic volume,left ventricular end-systolic volume and LVEF(P>0.05);However,the T1 and T2 values of hypertrophic and non-hypertrophic segments were increased in HCM patients. Compared with non-hypertrophic segment,the T1 and T2 values of hypertrophic segment increased,and the thickening rate of ventricular wall decreased significantly (P<0.05). Conclusion T1 and T2 of CMR tissue imaging parameters can detect HCM abnormalities before cardiac function parameters. In addition,even if the myocardial thickness was normal,the values of T1 and T2 were higher than those of normal people,suggesting that the change of tissue characteristics precedes the morphological and functional remodeling of HCM. Therefore,the measurement of T1 and T2 values can provide value for the early myocardial changes of HCM

参考文献/References:

[1]Ma?ek ?A,Werys K,K?opotowski M,et al. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy comparison with late enhancement quantification[J]. Magn Reson Imaging,2015,33(6):718-724.

[2]Task Force members,Elliott PM,Anastasakis A,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J,2014,35(39):2733-2779.

[3]Gastl M,Gotschy A,von Spiczak J,et al. Cardiovascular magnetic resonance T2* mapping for structural alterations in hypertrophic cardiomyopathy[J]. Eur J Radiol Open,2019,6:78-84.

[4]Huelnhagen T,Ku MC,Reimann HM,et al. Myocardial effective transverse relaxation time T2 * is elevated in hypertrophic cardiomyopathy:a 7.0 T magnetic resonance imaging study[J]. Sci Rep,2018,8(1):3974.

[5]朱黎,赵新湘,孙林. MR心肌首过灌注成像评估肥厚型心肌病心肌缺血[J]. 中国医学影像技术,2018,34(2):214-218.

[6]Ferreira VM,Piechnik SK,Dall’Armellina E,et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy:a comparison to T2-weighted cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2012,14(1):42.

[7]Huang L,Ran L,Zhao P,et al. MRI native T1 and T2 mapping of myocardial segments in hypertrophic cardiomyopathy:tissue remodeling manifested prior to structure?changes[J]. Br J Radiol,2019,92(1104):20190634.

[8] Minegishi S,Kato S,Takase-Minegishi K,et al. Native T1 time and extracellular volume fraction in differentiation of normal myocardium from non-ischemic dilated and hypertrophic cardiomyopathy myocardium:a systematic review and meta-analysis[J]. Int J Cardiol Heart Vasc,2019,25:100422.

[9]Ferreira VM,Piechnik SK,Dall’Armellina E,et al. Native T1-mapping detects the location,extent and patterns of acute myocarditis without the need for gadolinium contrast agents[J]. J Cardiovasc Magn Reson,2014,16(1):36.

[10]Bull S,White SK,Piechnik SK,et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis[J]. Heart,2013,99(13):932-937.

[11]Ho CY,López B,Coelho-Filho OR,et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy[J]. N Engl J Med,2010,363(6):552-563.

[12]Treibel TA,Fontana M,Maestrini V,et al. Automatic measurement of the myocardial interstitium:synthetic extracellular volume quantification without hematocrit sampling[J]. JACC Cardiovasc Imaging,2016,9(1):54-63.

[13]Abdel-Aty H,Cocker M,Strohm O,et al. Abnormalities in T2-weighted cardiovascular magnetic resonance images of hypertrophic cardiomyopathy:regional distribution and relation to late gadolinium enhancement and severity of hypertrophy[J]. J Magn Reson Imaging,2008,28(1):242-245

[14]Shi RY,An DA,Chen BH,et al. High T2-weighted signal intensity is associated with myocardial deformation in hypertrophic cardiomyopathy[J]. Sci Rep,2019,9(1):2644.

[15]Gommans DF,Cramer GE,Bakker J,et al. High T2-weighted signal intensity is associated with elevated troponin T in hypertrophic cardiomyopathy[J]. Heart,2017,103(4):293-299.

相似文献/References:

[1]王皎.室性期前收缩性心肌病诊疗进展[J].心血管病学进展,2020,(6):563.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.001]
 WANG Jiao.Diagnosis and Treatment of Premature Ventricular Contraction-induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(9):563.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.001]
[2]刘玉辉 王盼盼 陈椿.心房颤动性心肌病临床研究进展[J].心血管病学进展,2020,(12):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
 LIU Yuhui,WANG Panpan,CHEN Chun.Atrial Fibrillation-induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(9):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
[3]王前程 刘伟涛 周忠江.提高对甲状腺素转运蛋白淀粉样变性心肌病诊治的认识[J].心血管病学进展,2021,(3):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
 WANG Qiancheng,LIU Weitao,ZHOU Zhongjiang.To Improve the Recognition of Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(9):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
[4]杭成文 崔鸣.Myomesin基因家族及其相关疾病的研究进展[J].心血管病学进展,2021,(4):314.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.007]
 HANG Chengwen,CUI Ming.Myomesin Gene Family and Related Diseases[J].Advances in Cardiovascular Diseases,2021,(9):314.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.007]
[5]徐尧 蔡衡 李洪仕.心房颤动合并心力衰竭的导管消融治疗[J].心血管病学进展,2021,(4):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
 XU Yao,CAI Heng,LI Hongshi.Role of Radiofrequency Ablation in Patients with Atrial Fibrillation and Heart Failure[J].Advances in Cardiovascular Diseases,2021,(9):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
[6]刘珊珊,王岳恒,赵卉霖.肥厚心肌病动态梗阻的研究进展[J].心血管病学进展,2021,(6):508.[doi:10.16806/j.cnki.issn.1004-3934.20.06.008]
 LIU Shanshan,WANG Yueheng,ZHAO Huilin.Dynamic Obstruction in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(9):508.[doi:10.16806/j.cnki.issn.1004-3934.20.06.008]
[7]黄勇淇 田龙海 杨龙.室性期前收缩心肌病[J].心血管病学进展,2022,(4):348.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.015]
 HUANG Yongqi,TIAN Longhai,YANG Long.Premature Ventricular Complexes Induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(9):348.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.015]
[8]王帅兵 刘江文 黄从新.神经氨酸酶1在心血管疾病中的研究进展[J].心血管病学进展,2023,(11):982.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.006]
 WANG Shuaibing,LIU Jiangwen,HUANG Congxin.NEU1 in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2023,(9):982.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.006]
[9]张昕彤 任卫东.心肌病的再认识——从遗传学出发的探索[J].心血管病学进展,2024,(11):961.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.001]
 REN Weidong,ZHANG Xintong.A New Recognition on CardiomyopathyIn-Depth Exploration of Genetics[J].Advances in Cardiovascular Diseases,2024,(9):961.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.001]

更新日期/Last Update: 2021-10-21